The metabolism of Prasugrel can be decreased when combined with Ticagrelor. The serum concentration of Ticagrelor can be increased when it is combined with Mifepristone. The serum concentration of Ticagrelor can be decreased when it is combined with Lumacaftor. The metabolism of Ticagrelor can be decreased when combined with Rucaparib. The serum concentration of Ticagrelor can be decreased when it is combined with Enzalutamide. The serum concentration of Ledipasvir can be increased when it is combined with Ticagrelor. The risk or severity of adverse effects can be increased when Nicergoline is combined with Ticagrelor. The serum concentration of Metoprolol can be increased when it is combined with Ticagrelor. The metabolism of Ximelagatran can be decreased when combined with Ticagrelor. The metabolism of Quinine can be decreased when combined with Ticagrelor. The metabolism of Paclitaxel can be decreased when combined with Ticagrelor. Ticagrelor may increase the anticoagulant activities of Fluindione. Pentoxifylline may increase the antiplatelet activities of Ticagrelor. Ticagrelor may increase the anticoagulant activities of Lepirudin. The metabolism of Ondansetron can be decreased when combined with Ticagrelor. The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Telithromycin resulting in a loss in efficacy. Ticagrelor may increase the anticoagulant activities of Ancrod. The metabolism of Ibuprofen can be decreased when combined with Ticagrelor. The metabolism of Sulfadiazine can be decreased when combined with Ticagrelor. Dipyridamole may increase the anticoagulant activities of Ticagrelor. The metabolism of Piroxicam can be decreased when combined with Ticagrelor. The metabolism of Formoterol can be decreased when combined with Ticagrelor. The metabolism of Selegiline can be decreased when combined with Ticagrelor. The serum concentration of Vincristine can be increased when it is combined with Ticagrelor. The metabolism of Troglitazone can be decreased when combined with Ticagrelor. The metabolism of Ticagrelor can be decreased when combined with Fluconazole. Ticagrelor may increase the anticoagulant activities of Argatroban. Acetylsalicylic acid may increase the antiplatelet activities of Ticagrelor. The metabolism of Carbinoxamine can be decreased when combined with Ticagrelor. The metabolism of Idarubicin can be decreased when combined with Ticagrelor. The risk or severity of adverse effects can be increased when Diflunisal is combined with Ticagrelor. The metabolism of Trabectedin can be decreased when combined with Ticagrelor. The serum concentration of Ubidecarenone can be increased when it is combined with Ticagrelor. The serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib. Ticagrelor may increase the anticoagulant activities of Higenamine. The metabolism of Lansoprazole can be decreased when combined with Ticagrelor. The metabolism of Losartan can be decreased when combined with Ticagrelor. The serum concentration of Ticagrelor can be increased when it is combined with Fosaprepitant. The serum concentration of Ticagrelor can be decreased when it is combined with Deferasirox. The metabolism of Ticagrelor can be decreased when combined with Erythromycin. Ticagrelor may increase the anticoagulant activities of Dextran 75. The metabolism of Doxepin can be decreased when combined with Ticagrelor. The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Sarilumab. Ramatroban may increase the anticoagulant activities of Ticagrelor. The metabolism of Torasemide can be decreased when combined with Ticagrelor. The metabolism of Dolasetron can be decreased when combined with Ticagrelor. The metabolism of Ticagrelor can be decreased when combined with Sildenafil. Ticagrelor may increase the anticoagulant activities of Certoparin. The metabolism of Zopiclone can be decreased when combined with Ticagrelor. The metabolism of Dopamine can be decreased when combined with Ticagrelor. The risk or severity of adverse effects can be increased when Balsalazide is combined with Ticagrelor. The metabolism of Valdecoxib can be decreased when combined with Ticagrelor. The risk or severity of adverse effects can be increased when Ticagrelor is combined with Collagenase clostridium histolyticum. The metabolism of Sulfamoxole can be decreased when combined with Ticagrelor. Resveratrol may increase the anticoagulant activities of Ticagrelor. The serum concentration of Ticagrelor can be increased when it is combined with Ceritinib. The metabolism of Warfarin can be decreased when combined with Ticagrelor. The serum concentration of Ticagrelor can be decreased when it is combined with St. John's Wort. The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ticagrelor. The risk or severity of adverse effects can be increased when Mesalazine is combined with Ticagrelor. The serum concentration of Digoxin can be increased when it is combined with Ticagrelor. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ticagrelor. Ticagrelor may increase the anticoagulant activities of Protein C. The serum concentration of Lovastatin can be increased when it is combined with Ticagrelor. Ticagrelor may increase the anticoagulant activities of Alteplase. Ticagrelor may increase the anticoagulant activities of Drotrecogin alfa. The metabolism of Ifosfamide can be decreased when combined with Ticagrelor. Ticagrelor may increase the anticoagulant activities of Letaxaban. The serum concentration of Ticagrelor can be increased when it is combined with Netupitant. The serum concentration of Tolvaptan can be increased when it is combined with Ticagrelor. Ticagrelor may increase the anticoagulant activities of Ardeparin. The metabolism of Cabozantinib can be decreased when combined with Ticagrelor. The serum concentration of Pazopanib can be increased when it is combined with Ticagrelor. The metabolism of Valsartan can be decreased when combined with Ticagrelor. The risk or severity of adverse effects can be increased when Ticagrelor is combined with Tositumomab. The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ticagrelor. The metabolism of Dicoumarol can be decreased when combined with Ticagrelor. The metabolism of Moclobemide can be decreased when combined with Ticagrelor. The serum concentration of Ticagrelor can be decreased when it is combined with Siltuximab. Andrographolide may increase the anticoagulant activities of Ticagrelor. The metabolism of Ticagrelor can be decreased when combined with Diltiazem. Eptifibatide may increase the anticoagulant activities of Ticagrelor. The metabolism of Thiamylal can be decreased when combined with Ticagrelor. Ticagrelor may increase the anticoagulant activities of Streptokinase. The metabolism of Antipyrine can be decreased when combined with Ticagrelor. The serum concentration of Ticagrelor can be increased when it is combined with Osimertinib. Beraprost may increase the anticoagulant activities of Ticagrelor. The metabolism of Etodolac can be decreased when combined with Ticagrelor. The metabolism of Trimipramine can be decreased when combined with Ticagrelor. Tipranavir may increase the antiplatelet activities of Ticagrelor. Ticagrelor may increase the anticoagulant activities of Anistreplase. The metabolism of Histamine can be decreased when combined with Ticagrelor. The metabolism of Aminophenazone can be decreased when combined with Ticagrelor. Ifenprodil may increase the anticoagulant activities of Ticagrelor. The metabolism of Clopidogrel can be decreased when combined with Ticagrelor. The metabolism of Zafirlukast can be decreased when combined with Ticagrelor. The metabolism of Ketoprofen can be decreased when combined with Ticagrelor. The serum concentration of Atorvastatin can be increased when it is combined with Ticagrelor. Ticagrelor may increase the anticoagulant activities of Ethyl biscoumacetate. The metabolism of Rosiglitazone can be decreased when combined with Ticagrelor. Ticagrelor may increase the anticoagulant activities of Reteplase. The serum concentration of Prucalopride can be increased when it is combined with Ticagrelor. The metabolism of Omeprazole can be decreased when combined with Ticagrelor. Vorapaxar may increase the anticoagulant activities of Ticagrelor. Ticagrelor may increase the anticoagulant activities of Fondaparinux. The metabolism of Loratadine can be decreased when combined with Ticagrelor. Omega-3 fatty acids may increase the antiplatelet activities of Ticagrelor. The metabolism of Tapentadol can be decreased when combined with Ticagrelor. The metabolism of Ketobemidone can be decreased when combined with Ticagrelor. Ticagrelor may increase the anticoagulant activities of Sulodexide. The metabolism of Ticagrelor can be decreased when combined with Atomoxetine. The serum concentration of Ticagrelor can be increased when it is combined with Luliconazole. The serum concentration of Ticagrelor can be decreased when it is combined with Brigatinib. The serum concentration of Naloxegol can be increased when it is combined with Ticagrelor. The metabolism of Lumiracoxib can be decreased when combined with Ticagrelor. The metabolism of Terbinafine can be decreased when combined with Ticagrelor. The metabolism of Ospemifene can be decreased when combined with Ticagrelor. The metabolism of Caffeine can be decreased when combined with Ticagrelor. Cangrelor may increase the anticoagulant activities of Ticagrelor. The metabolism of Zalcitabine can be decreased when combined with Ticagrelor. The serum concentration of Edoxaban can be increased when it is combined with Ticagrelor. The metabolism of Propofol can be decreased when combined with Ticagrelor. The metabolism of Leflunomide can be decreased when combined with Ticagrelor. The serum concentration of Afatinib can be increased when it is combined with Ticagrelor. The risk or severity of adverse effects can be increased when Cabergoline is combined with Ticagrelor. Tesmilifene may increase the anticoagulant activities of Ticagrelor. The metabolism of Fluoxetine can be decreased when combined with Ticagrelor. Vitamin E may increase the antiplatelet activities of Ticagrelor. The metabolism of Pravastatin can be decreased when combined with Ticagrelor. The metabolism of Flunitrazepam can be decreased when combined with Ticagrelor.